Furthermore, in line with our findings, their data indicate that 6‐MP treatment may also be effective in ovarian carcinomas harboring NUDT15–RB1 codeletions, extending the therapeutic potential beyond PRCA. This evidence concerns the gene RB1 and ovarian carcinoma.